BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Tuesday, April 30, 2024
Breaking News: Try BioWorld for free for two weeks
See today's BioWorld Science
Home
» New NLRP3 inflammasome inhibitors disclosed in Merck Sharp & Dohme patent
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Musculoskeletal
New NLRP3 inflammasome inhibitors disclosed in Merck Sharp & Dohme patent
April 17, 2024
No Comments
Merck Sharp & Dohme LLC has disclosed phthalazine derivatives acting as NLRP3 inflammasome inhibitors reported to be useful for the treatment of atherosclerosis, nonalcoholic steatohepatitis (NASH; metabolic dysfunction-associated steatohepatitis [MASH]), neuroinflammation, inflammatory skin disease, inflammatory joint disease, autoimmune disease, Alzheimer’s disease and Parkinson’s disease, among others.
BioWorld Science
Musculoskeletal
Patents